Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960284 | 0.75 | ATR (0.43) | — | |
| SCHEMBL18701721 | 0.69 | DPP4 (0.43) | KMT2ADAO | |
| SCHEMBL5237466 | 0.67 | PDK1 (0.38) | KMT2ANPC1POLBRAB9A | |
| SCHEMBL21875055 | 0.67 | KMT2A (0.45) | KMT2APOLBRAB9ADAOABL1 | |
| SCHEMBL23927263 | 0.66 | KEAP1 (0.30) | KMT2A | |
| SCHEMBL23927258 | 0.66 | KMT2A (0.33) | KMT2ADAO | |
| SCHEMBL23927271 | 0.66 | KDR (0.36) | KMT2ARAB9A | |
| SCHEMBL3475291 | 0.65 | SLC2A1 (0.42) | KMT2ANPC1RAB9A | |
| SCHEMBL2094466 | 0.64 | ALDH1A1 (0.51) | KMT2ANPC1POLBRAB9A | |
| SCHEMBL2093660 | 0.64 | MEN1 (0.56) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | KMT2A 23/4885NPC1 3614/4885POLB 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.